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hepatocellular carcinoma cells in vitro in a
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Background: Hepatocellular carcinoma (HCC) has a high incidence and mortality. Radiotherapy and sorafenib have
proven effective for HCC. Here, we investigated whether sorafenib modulated the response of HCC cells to
irradiation in vitro, effect of timing of sorafenib, and the underlying mechanisms.
Methods: Cell viability of the HCC cell lines, SMMC-7721 and Bel-7402, was examined by the 3-(4,5-dimethylthiazol-
2-yl)-5(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2 H-terazolium (MTT) assays. Clonogenic growth assays of
SMMC-7721 and Bel-7402 were determined by colony formation assays. DNA damage was assessed by monitoring
γ-HAX foci in irradiated cells with immunofluorescence microscopy, and cell cycle distribution changes were
examined by flow cytometry. Effects of sorafenib (15 μM) added 30 min prior to radiation (pre-irradiation sorafenib)
of SMMC-7721 and BEL-7402 or 24 h post-irradiation (post-irradiation sorafenib) on irradiated SMMC-7721 and
BEL-7402 cells were compared to those of radiation alone or no treatment.
Results: The effect of sorafenib was dependent on its time of addition in relationship to irradiation of cells.
Pre-irradiation sorafenib did not significantly affect the viability of SMMC-7221 and BEL-7402 cells compared with
irradiation treatment alone. In contrast, post-irradiation sorafenib increased the sensitivity of irradiated SMMC-7221
and BEL-7402 cells significantly in a time-dependent manner. Pre-irradiation sorafenib significantly increased the
surviving fraction of SMMC-7221 and BEL-7402 cells in clonogenic assays whereas post-irradiation sorafenib
significantly reduced the surviving fractions of SMMC-7221 and BEL-7402 cells. SMMC-7721 cells treated with
sorafenib 30 min before irradiation had significantly fewer cells with γ-H2AX foci (23.8 ± 2.9%) than SMMC-7721 cells
receiving radiation alone (59.9 ± 2.4; P < 0.001). Similarly, BEL-7402 cells receiving sorafenib prior to irradiation had
significantly fewer cells with γ-H2AX foci (46.4 ± 3.8%) than those receiving radiation alone (25.0 ± 3.0%; P < 0.001).
In addition, irradiation (6 Gy) caused a significant increase in the percentage of both SMMC-7721 and BEL-7402 cells
in G2/M at 12 to 16 h post irradiation, which was markedly delayed by pre-irradiation sorafenib.
Conclusions: Sorafenib combined with irradiation exerted a schedule-dependent effect in HCC cells in vitro, which
has significant implications for the combined use of sorafenib and radiotherapy for HCC patients.
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Primary hepatocellular carcinoma is the 6th most com-
mon malignancy in the world and ranks 3rd among
causes of cancer-related death. Hepatocellular carcinoma
is prevalent in China and accounts for 55% of all hepato-
cellular carcinoma cases in the world [1]. Despite the
best therapeutic regimen currently available, hepatocel-
lular carcinoma has a dismal outcome with the five-year
survival rate of 3% -10% for metastasized HCC and 28%
for locally confined HCC. Approximately 80% of hepato-
cellular carcinoma patients have inoperable cancer at the
time of diagnosis [2]. The median survival for patients
with inoperable hepatocellular carcinoma is generally
about 6 months [2].
Recently, adjuvant radiotherapy has shown promise as
a treatment for inoperable hepatocellular carcinoma with
a response rate of 30 ~ 67% [3-5]. Since radiotherapy is
limited by poor tolerance of radiation in adjacent normal
tissues, and regional radiotherapy has no tangible effect
on intrahepatic and distant metastasis, agents that boost
the sensitivity to radiotherapy are sought. Sorafenib is a
multikinase inhibitor with anti-proliferative and anti-
angiogenic effects. It inhibits the activity of the serine/
threonine kinases c-Raf and B-Raf; the mitogen-
activated protein kinases MEK and ERK; vascular endo-
thelial growth factor receptors (VEGF); platelet-derived
growth factor receptors (PDGFR); the cytokine receptor
c-KIT; the receptor tyrosine kinases Flt-3 and RET; and
the Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) pathway [6]. Phase III clinical
studies have shown that sorafenib is efficacious in
patients with advanced hepatocellular carcinoma [7,8],
and sorafenib is the most recent drug approved for
hepatocellular carcinoma. However, sorafenib only mod-
estly improves the outcome of hepatocellular carcinoma
patients, prolonging the median survival of patients with
inoperable hepatocellular carcinoma by less than
3 months [7]. Mechanistically, sorafenib increases apop-
tosis of the hepatocellular carcinoma cells, PLC/PRF/5
and HepG2 cells [9] as well as some breast cancers,
colorectal carcinomas, osteosarcomas, and glioblasto-
masbut not all types of tumor cells [10]. Sorafenib may
augment radiotherapy of HCC because administration of
sorafenib post-irradiation markedly potentiated the in-
hibitory effect of irradiation on growth of mouse colo-
rectal cancer xenografts compared to irradiation alone
[10]. However, the combination of irradiation and con-
current sorafenib administration had no significant effect
on tumor growth [10]. Suen et al. [11] investigated the
combined effect of sorafenib and irradiation on colorec-
tal cancer cells: only sorafenib given post irradiation
augments the inhibitory effects of irradiation on clono-
genic growth. Interestingly, three renal cell carcinoma
patients who relapsed under sorafenib were subsequentlyco-administered radiotherapy [12]. Sorafenib treatment
was administered both prior to and concurrently with
radiation [12]. In these three RCC cases, the tumor mass
shrunk, pain diminished or was abolished, and patients
reported no late side effects [12].
We hypothesized that sorafenib may also boost the ef-
ficacy of irradiation on HCC in a schedule-dependent
manner. A case report of a patient with inoperable HCC
who was initially treated with sorafenib provides support
of interaction between radiotherapy and sorafenib during
treatment of HCC [13]. The patient’s history included
sorafenib treatment, its subsequent discontinuation due
to side effects, unchecked tumor growth, treatment with
both radiotherapy and sorafenib, tumor shrinkage, and
the recurrence of sorafenib-related rash [13]. Currently,
optimization of combined irradiation and sorafenib in
hepatocellular carcinoma has not been described, and
the mechanisms of irradiation enhanced by sorafenib are
still ambiguous. We investigated the effect of combined
radiotherapy and sorafenib on two hepatocellular carcin-
oma cell lines, SMMC-7721 and BEL-7402, and the
underlying mechanisms of interaction.
Methods
Cell lines and agents
Human hepatocellular carcinoma cell lines, SMMC-7721
and Bel-7402, were obtained from Nanfang Hospital of
Southern Medical University, Guangzhou, Guangdong,
China [14], and were cultured in RPMI-1640 supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS) (Hyclone, Logan City, Utah) at 37°C in a humidi-
fied atmosphere containing 5% CO2. Sorafenib (Bayer,
Leverkusen, Germany) was dissolved in dimethyl sulfox-







(Promega, Madison, WI) were performed as instructed
by the manufacturer to assess cell viability. Briefly,
SMMC-7721 (3 Χ 103 cells/well) and BEL-7402 cells
(4 ×103) were seeded into 96-well plates in quadrupli-
cate. After incubation for 1 d, cells were treated with
sorafenib 30 min before (pre-irradiation sorafenib) or
24 h following irradiation (post-irradiation sorafenib).
Cells were irradiated at the indicated doses using a 60Co
irradiator. Cell viability was measured on d0 to d6 after
irradiation. Absorbance values were shown as the per-
centage of the treated samples relative to the controls
which received neither irradiation nor sorafenib. Inhib-
ition of cell growth was measured as the percentage of
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as follows: % of viable cells = ODT/ODC x 100%, where
ODT is the average OD value of the treatment samples,
and ODC is the average OD value of the control sam-
ples. Results were analyzed using the CalcuSyn software
program (Biosoft, Cambridge, UK). Combination indices
(CI) were used to assess the interaction between the two
treatment modalities.Apoptotic study and cell cycle analysis
SMMC-7721 and BEL-7402 cells were irradiated, treated
with sorafenib for 30 min followed by irradiation (pre-ir-
radiation sorafenib), or irradiated and treated 24 h later
with sorafenib (post-irradiation sorafenib). Apoptosis
was detected in cells washed with phosphate buffered sa-
line (PBS) at 48 h post-irradiation (irradiated controls,
pre-irradiation sorafenib) or 72 h post-irradiation (post-
irradiation sorafenib) by staining with annexin V and
propidium iodide as instructed by the manufacturer (BD
Biosciences, Franklin Lake, NJ). Stained cells were ana-
lyzed by flow cytometry with a FACSCalibur flow cyt-
ometer (BD Biosciences). For cell cycle analysis, treated
cells were washed once with PBS, trypsinized, washed in
PBS with 2% FBS, fixed in ice-cold ethanol for at least
1 h, washed, stained with propidium iodide (30 μg/mL),
and treated with RNase (0.6 mg/ml) in PBS plus 0.5%
(v/v) Tween 20 and 2% FBS. Stained cells were analyzed
on a FACSCalibur flow cytometer (BD Biosciences) by
using the CellQuest software. Mod-Fit program (Verity
Software House Inc., Topsham, ME) was used to
analyze the cell-cycle profiles.Colony formation assays
This procedure was performed as previously described
[15]. Briefly, cells were irradiated at a dose of 0, 2, 4, and
8 Gy alone or in combination with sorafenib adminis-
tered 30 min prior to (pre-irradiation sorafenib) or 24 h
following irradiation (post-irradiation sorafenib). After
incubation of 12 d (SMMC-7721) or 14 d (BEL-7402),
cells were stained with 0.5% crystal violet in absolute
ethanol, and colonies containing more than 50 cells
were counted under a dissection microscope. Clono-
genic survival curves were constructed by fitting the
average survival levels. Subsequent experiments utilized
a radiation dose of 6 Gy because the percentage of cells
remaining after 8 Gy (SMMC-7721: 0.9-4%; BEL-7402:
2-5%) was too low for analysis. SMMC-7721 and BEL-
7402 cells in subsequent experiments received one of
the four treatments: (a) none (control), (b) 6 Gy radi-
ation, (c) 15 μM sorafenib 30 min before 6 Gy radi-
ation, or (d) 6 Gy radiation followed 24 h later with
15 μM sorafenib.DNA damage immunofluorescence microscopy
Immunofluorescence microscopy was done as previously
described [16]. Rabbit anti-γ-H2AX antibody (serine 139;
Abcam, Cambridge, MA), and secondary antibodies Alex
Fluor 488 goat anti-rabbit IgG (Invitrogen, Carlsbad, CA)
were used. Nuclear staining was done by using 4’, 6-diami-
dino-2-phenylindole (DAPI) (Vector Laboratories, USA).
A cell containing more than 10 γ-H2AX foci was consid-
ered to be positive for damages to DNA.Cell cycle G2/M distribution assay
After the indicated time period, cells were rinsed with
PBS, fixed with 70% ethanol, and incubated overnight at
-20°C. Fixed cells were washed and suspended in 500 μl
of staining solution (50mcg/ml of propidium iodide,
100mcg/ml RNAase and 0.2% Triton X-100) for 30 min.
The fluorescence associated with PI-bound DNA was
measured by flow cytometry (Beckman Coulter, cytomics
FC 500, CA). Cell cycle profiles of G2/M phase were cal-
culated using MultiCycle software.Cell proliferation assays
SMMC-7721 and BEL-7402 cells were plated at 1 x 103
cells per well in collagen-coated 96-well plates. Cell pro-
liferation assays were performed by using the Cell
Counting Kit-8 (CCK8) (Dojindo, Kumamoto, Japan)
according to the manufacturer's protocol. Briefly, a 10 μL
of CCK-8 solution was added to each well and incu-
bated at 37°C for 2 h in a humidified CO2 incubator.
Optical density (OD) was measured at 450 nm using a
Microplate Reader (Bio-Tek Instruments, Winooski, VT)
and the proliferation index was calculated as the experi-
mental OD value/control OD value. Each experiment
was done in quadruplicate and at least three times
independently.Apoptosis assays
After incubation for 0 h, 24 h, or 48 h after sorafenib
treatment, cells were harvested, rinsed, and stained with
Annexin V-FITC and propidium iodide, as previously
described [17].Statistical analyses
Normally distributed continuous variables were com-
pared by one-way analysis of variance (ANOVA). When
a significant difference between groups was apparent,
multiple comparisons of means were performed using
the Dunnett test. Data are presented as mean ± standard
deviation (SD). All statistical assessments were two-
sided and evaluated at the 0.05 level of significant differ-
ence. Statistical analyses were performed using SPSS
15.0 statistics software (SPSS Inc, Chicago, IL).
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Sorafenib modulated radio sensitivity of hepatocellular
carcinoma cells in a schedule-dependent manner
To investigate whether sorafenib modulated the re-
sponse of hepatocellular carcinoma cells to radiation, we
added sorafenib 30 min prior to or 24 h following irradi-
ation of hepatocellular carcinoma cells SMMC-7721 and
BEL-7402 and measured cellular viability by MTT for
6 days (Figure 1). Pre-irradiation sorafenib did not sig-
nificantly affect the viability of SMMC-7221 and BEL-
7402 cells (Figure 1A and 1B) (P > 0.05). In contrast,
post-irradiation sorafenib reduced the sensitivity of irra-
diated SMMC-7221 and BEL-7402 cells significantly in aFigure 1 Effect of sorafenib treatment on cell viability of irradiated SM
radiation, sorafenib 30 min prior to irradiation (pre-IR sorafenib), or 24 h po
measure the viability of irradiated, treated cells. Cell viability was significant
pre-irradiation sorafenib group. Mean values were compared by using ANOtime-dependent manner (Figure 1A and 1B) (P < 0.05).
These findings suggested that sorafenib modulated the
radio sensitivity of hepatocellular carcinoma cells in a
schedule-dependent manner in vitro.
To further assess the effect of sorafenib on the radio
sensitivity of HCC cell lines, we performed clonogenic
assays. Radiation caused a dose-dependent cytotoxic ef-
fect on SMMC-7221 and BEL-7402 cells with less than
20% of cells surviving at 4 Gy and less than 0.1% of cells
surviving at 10 Gy. The surviving fraction of SMMC-
7221 and BEL-7402 cells was 0.15 ± 0.05 and 0.24 ± 0.02,
respectively, at an irradiation dose of 4 Gy. Pre-
irradiation sorafenib significantly increased the survivingMC-7721 (A) and BEL-7402 cells (B). Cells were treated with
st irradiation (post-IR sorafenib), and MTT assays were performed to
ly lower in the post-irradiation sorafenib group versus the irradiation or
VA. Mean ± SD (n = 3). *P < 0.05 vs. Radiation group.
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ample, sorafenib increased survival of irradiated (4 Gy)
SMMC-7221 to 0.21 ± 0.04 and irradiated (4 Gy) BEL-
072 to 0.40 ± 0.03 (Figure 2A and 2B; Table 1) (P < 0.05
in both). These data suggested that sorafenib given prior
to irradiation rendered hepatocellular carcinoma cells
more radio resistant. By contrast, post-irradiation sorafe-
nib added 24 hr post irradiation (4 Gy) decreased the
surviving fraction of SMMC-7221 to 0.11 ± 0.01, and
that of BEL-7402 cells to 0.21 ± 0.03 (Figure 2C and 2D,
respectively; Table 1) (P < 0.05 for both). These data
indicated that sorafenib given 24 h post irradiation
increased the radio sensitivity of hepatocellular carcin-
oma cells. The above findings altogether suggested that
sorafenib exerted a schedule-dependent effect on the
sensitivity of hepatocellular carcinoma cells to radiation.Figure 2 Clonogenic survival of human hepatocellular carcinoma cell
without sorafenib. A, B Sorafenib (15 mM) was added 30 min prior to irra
and sorafenib was added 24 h post irradiation (post-IR sorafenib). Survival f
untreated cells as the denominator to illustrate independent cytotoxic effePre-radiation sorafenib increased ability of irradiated
hepatocellular carcinoma cells to subsequently repair
DNA damage in vitro
Initially, we hypothesized that pre-radiation sorafenib
increased the sensitivity of irradiated hepatocellular car-
cinoma cells to the formation of DNA double-strand
breaks (DSBs). We monitored the formation of DSBs in
SMMC-7721 and BEL-7402 cells by examining γ-H2AX
induced foci by immunofluorescence. Hepatocellular
carcinoma cells were treated with sorafenib for 30 min
prior to radiation (6 Gy). Our immunofluorescence
assays showed that 94.6 ± 3.5% of irradiated SMMC-
7721and 64.7 ± 2.9% of irradiated BEL-7402 cells were
positive for γ-H2AX. Similarly, 93.9 ± 4.7% and 62.7 ±
4.0% of SMMC-7721 and BEL-7402 cells that received
both radiation and sorafenib were positive for γ-H2AXs SMMC-7721 (A, C) and BEL-7402 (B, D) after irradiation with or
diation of cells (pre-IR sorafenib). C, D. Cells were irradiated (0-10 Gy)
raction (SF) was calculated by using the mean plating efficiency (PE) of
cts of sorafenib; linear quadratic (LQ) equation was fitted to data.
Table 1 Mean values for and (and standard errors of the
means) calculated by fitting the LQ equation to
clonogenic survival
α SEM β SEM
SMMC-7721
IR -1.271 0.028 0.866 0.020
IR ± Sorafenib pre -1.295 0.021 0.850 0.011
(Sorafenib delivered 30 min pre-IR)
IR ± Sorafenib post -1.145 0.035 0.927 0.017
(Sorafenib delivered 24 h post-IR)
BEL-7402
IR -1.384 0.013 0.804 0.007
IR ± Sorafenib pre -1.412 0.014 0.785 0.008
(Sorafenib delivered 30 min pre-IR)
IR ± Sorafenib post -1.331 0.026 0.831 0.136
(Sorafenib delivered 24 h post-IR)
Abbreviations: LQ: linear quadratic; IR: irradiation; SEM: standard error of the
mean.
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cated that pre-irradiation sorafenib did not promote
radiation-induced DSBs. We hypothesized that sorafenib
may promote the repair of radiation-induced DNA
damages. Thus, we compared the percentage of
sorafenib-treated (30 min prior), irradiated (6 Gy) cells
for γ-H2AX immunofluorescence to radiation treated
cells. At 6 h post irradiation, irradiated SMMC-7721
cells had significantly higher γ-H2AX immunofluores-
cence (59.9 ± 2.4%) than pre-radiation sorafenib-treated,
irradiated SMMC-7721 cells (23.8 ± 2.9%) (P < 0.001).
Similarly, pre-radiation sorafenib-treated, irradiated
BEL-7402 cells had fewer γ-H2AX positive cells (25.0 ±
3.0%) than only irradiated BEL-7402 cells (46.4 ± 3.8%)
(P < 0.001) (Figure 3A to 3C).
Pre-irradiation sorafenib delayed the activation of
radiation-induced G2/M checkpoint in hepatocellular
carcinoma cells
Radiation-induced DNA damages lead to the activation
of G2/M checkpoint. We investigated whether sorafenib
given prior to or following irradiation of hepatocellular
carcinoma cells impacted radiation-induced changes in
distribution of cell cycle stages. Sorafenib alone induced
no apparent changes in cell cycle distribution of either
SMMC-7721and BEL-7402cells while, as expected,
irradiation (6 Gy) caused a significant increase in the
percentage of both SMMC-7721 and BEL-7402cells in
G2/M at 12 to 16 h post radiation (Figure 4). Pre-
irradiation sorafenib also induced an accumulation of
the hepatocellular carcinoma cells in G2/M, but this
increase in the percentage of cells in G2/M was signifi-
cantly delayed to 24 to 30 h post irradiation in SMMC-
7721 cells and BEL-7402 cells.Sorafenib induced apoptosis of hepatocellular carcinoma
cells in vitro
Sorafenib reduced proliferation of hepatocellular carcin-
oma cells in CCK8 assays with an IC50 of 25.09 ±
4.49 μM for SMMC-7721 cells and an IC50 of 28.90 ±
1.07 μM for BEL-7402 cells. To examine whether sorafe-
nib induced apoptosis of the hepatocellular carcinoma
cells, SMMC-7721and BEL-7402 cells were treated with
sorafenib alone. After 24 h, cells were stained with
annexin V and propidium iodide to assess percentage of
cells undergoing apoptosis. The apoptotic rate in un-
treated SMMC-7721 (3.4 ± 2.2%) significantly increased
more than 4 fold to 18.3 ± 2.9% (P < 0.001) in sorafenib-
treated SMMC-7721 (Figure 5A). Sorafenib treatment
also increased the apoptotic rate in BEL-7402 cells from
7.2 ± 1.5% to 16.1 ± 2.7% (P < 0.001) (Figure 5B). Radi-
ation did not induce apparent apoptosis of the hepato-
cellular carcinoma cells SMMC-7721 (6.1 ± 1.0%)
compared to controls (4.5 ± 2.3%) or the BEL-7402 cells
(8.2 ± 2.1%,vs8.0 ± 1.5% in controls). Interestingly, pre-
irradiation sorafenib significantly increased the number
of apoptotic cells (SMMC-7721, 18.3 ± 2.0%, P < 0.05 vs.
controls; BEL-7402, 17.0 ± 2.4%, P < 0.05 vs. controls).
Post-irradiation sorafenib treatment significantly
increased the number of apoptotic cells (SMMC-7721,
15.9 ± 1.8%, P < 0.05 vs. controls; BEL-7402, 14.2 ± 2.5%,
P < 0.05 vs. controls) but to a lesser extent than sorafe-
nib treatment alone. Both pre-irradiation sorafenib and
post-irradiation sorafenib induced apoptosis in the hepa-
tocellular cells to a similar extent.
Discussion
Here, we showed that sorafenib modulated the response
of hepatocellular carcinoma cells to radiation and, fur-
thermore, this modulation was schedule-dependent. We
found that post-irradiation sorafenib radio sensitized
hepatocellular carcinoma cells by inhibiting the clono-
genic growth of the hepatocellular carcinoma cells. In
contrast, pre-irradiation sorafenib did not radio sensitize
these hepatocellular carcinoma cells in vitro, which is
similar to the findings in colorectal carcinoma [10,11].
Wilson and colleagues [11] investigated the effect of dif-
ferent schedules of sorafenib against irradiated colorectal
cancer and pancreatic cancer cells. Only sorafenib given
24 h post irradiation, but not concurrently, potentiated
the inhibition of clonogenic growth of irradiated cancer
cells [11]. In addition, Plastaras et al. [10] found that ra-
diation alone or sorafenib treatment prior to radiation
did not significantly reduce the growth of mouse colo-
rectal cancer xenografts. These above findings suggest
that sorafenib exerts a schedule-dependent effect on
colorectal carcinoma cells with post-irradiation sorafenib
being the most effective in inhibiting tumor growth in
mouse models.
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Figure 3 (See legend on next page.)
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Figure 3 Effect of sorafenib on DNA damage of irradiated SMMC-7721 and BEL-7402 cells. Treated cells were stained with DAPI and
anti- γ-H2AX antibody. A. Sorafenib was added to SMMC-7721 and BEL-7402 cells 30 min prior to their irradiation (6 Gy). B. Post-irradiation
sorafenib treated cells were incubated for 6 h before staining. C. Percentage of cells with ≥ 10 γ-H2AX foci. Comparisons of mean values were
performed using the independent two sample t test. Mean ± SD (n = 3). *P < 0.05 vs. the radiation group.
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lated by two main cell death pathways: interphase
apoptotic cell death pathway and mitotic catastrophe
[16,18]. Radiation induces mitotic catastrophe [18,19]
which occurs in cells with unrepaired DNA damage
that prematurely enter mitosis. Mitotic catastrophe isFigure 4 Effects of sorafenib treatments on cell cycle distribution of S
(radiation), 15 μM sorafenib 30 min before 6 Gy radiation (radiation + prera
sorafenib (radiation + post radiation sorafenib), or untreated (control). Fixed
content by flow cytometry. A. SMMC-7721. B. BEL-7402. Percentage of hep
were performed by using ANOVA. Mean ± SD (n = 3). *P < 0.05 vs. the radiaregulated by at least p53, survivin, cell-cycle check-
point proteins, and cell-cycle specific kinases [20]. To
assess whether the schedule-dependent effect of sorafe-
nib on irradiated cells is associated with mitotic ca-
tastrophe, we monitored DNA damage in irradiated
hepatocellular carcinoma cells by examining γ-H2AXMMC-7721 and BEL-7402. Cells were treated with 6 Gy radiation
diation sorafenib), or radiation followed 24 hrs later with 15 μM
cells were stained with propidium iodide and analyzed for DNA
atocellular carcinoma cells in G2 phase. Comparisons of mean values
tion group.
Figure 5 Effect of sorafenib on apoptosis of irradiated HCC cells. Sorafenib promoted apoptosis of hepatocellular carcinoma (HCC) cells with
or without radiation but had no delaying effect. Cells were treated with 15 μM sorafenib for 30 min prior to 6 Gy irradiation. (A) SMMC-7712 cells.
(B) BEL-7402 cells. Cells were collected at indicated times after the last treatment, and stained with Annexin V-FITC and propidium iodide. Mean ±
SEM of three independent experiments.
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sorafenib treatment had no effect on the formation of
DNA DSBs, but promoted repair of DNA damages, which
could lessen the chance of mitotic catastrophe. DNA dam-
age had been almost completely repaired in the irradiated
hepatocellular carcinoma cells since less than 5% of the
irradiated cells contained significant DNA damage (≥ 10
γ-H2AX foci). We speculate that post-irradiation sorafenib
did not increase repair of DNA damages in HCC. The dis-
tinct effects on DNA repair by the two schedules of sora-
fenib may partially explain the enhanced HCC viability
with pre-irradiation sorafenib compared to the lower cell
viability in irradiated HCC samples treated with sorafenib
24 post radiation.
The activation of cell cycle checkpoints plays a signifi-
cant role in the DNA damage response. It prevents
damaged cells from entering the next phase of the cell
cycle. Prolonged G2 arrest appears to contribute to the
ability of the cell to survive radiation [21,22]. As
expected, we found that irradiation induced the activa-
tion of the G2/M checkpoint in hepatocellular carcin-
oma cells at 16 h post irradiation. Additionally, we
observed that pre-irradiation sorafenib delayed the onset
of the G2/M checkpoint, which could allow more time
for the irradiated hepatocellular carcinoma cells to repair
DNA damages. Our clonogenic assays showed that sora-
fenib given prior to irradiation rendered hepatocellular
carcinoma cells more radio resistant, which could be
due to the delayed onset of the G2/M checkpoint, allow-
ing the irradiated cells more time to repair DNAdamages. As expected, HCC cells treated with post-
irradiation sorafenib had no effect on the G2/M peak at
16 hrs post radiation.
As the current study was carried out in vitro, we did
not examine the anti-angiogenic effect of sorafenib on
radio sensitivity in hepatocellular carcinoma cells. We
found that sorafenib exerts a schedule-dependent effect
on HCC radio sensitivity, which could be of significance
for the treatment of hepatocellular carcinoma patients
with sorafenib in combination with adjuvant radiother-
apy. Our findings suggest that the efficacy of sorafenib-
based therapy in combination with radiotherapy may
depend on the timing of sorafenib administration rela-
tive to that of radiotherapy. On the basis of our in vitro
studies, we speculate that post-irradiation sorafenib
could be more effective in potentiating tumor inhibitory
effect of radiotherapy. Further studies are needed to
confirm this schedule-dependent effect of sorafenib in
animal models bearing human hepatocellular carcinoma
xenografts and in clinical studies.
Conclusions
Sorafenib combined with irradiation exerted a schedule-
dependent effect in HCC cells in vitro.Sorafenib given
30 min prior to irradiation reduced the anti-proliferative
effects of irradiation against HCC whereas sorafenib
given 24 hr after irradiation increased the anti-tumor
effects against HCC. These results have significant impli-
cations for the combined use of sorafenib and radiother-
apy against HCC in the clinic.
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